News

David Eichenbaum, MD, discussed the status of the technology at the Retina 2024 meeting in Maui.

Glenn J. Jaffe, MD, discusses the multifactorial complexities of treating patients with geographic atrophy.

The FDA previously granted Regenerative Medicine Advanced Therapy (RMAT) designation and orphan drug designation to ATSN-101 for the treatment of LCA1.

The commercial release of OcuLenz is planned for the first half of 2024. Ocutrx is collaborating with Medicare and insurance providers to ensure the headset's affordability and accessibility.

NIDEK Co. Ltd. has made a financial donation to Orbis International to support Orbis’s artificial intelligence (AI)-based screening services in Vietnam.

According to the company, MicroPine, currently in late phase III for pediatric progressive myopia, will complement Eyenovia’s commercial-stage asset, Mydcombi, as well as its pre-PDUFA candidate, APP13007.

The kiosk is the first to offer self-service retinal imaging, empowering individuals to capture their own images.

Advances enhance clinical decision-making in screening cases at risk of iatrogenic ectasia.

The Annual Gala will be held on February 8 from 6 to 9 pm Pacific Standard Time.

David Hutton of Ophthalmology Times talks with Eric Donnenfeld, MD about his presentation "Small Aperture IOL for Irregular Corneas" at this year's Hawaiian Eye and Retina 2024 Meeting.

According to the Advanced Research Projects Agency for Health, its program aims to transplant human eyes and reestablish visual connection to the brain.

Patient selection is important.

David Hutton of Ophthalmology Times talks with William Trattler, MD, about his presentation "Toric IOL pearls for Correcting Lower Levels of Astigmatism" at this year's Hawaiian Eye and Retina 2024 Meeting.

Varun Chaudhary, MD, FRCSC, addressed the big questions in treating patients with retinal vascular diseases at the Retina 2024 meeting in Maui.

GreenMan app provides patients an opportunity to test drive various IOL options before cataract surgery via virtual and augmented reality.

The first step in management is increasing the time spent outside

The goal is to understand how individuals with CVI interact with their visual world

Vascular compromise is the most ominous early adverse event that can occur when a filler is unintentionally injected into a blood vessel.

David Hutton of Ophthalmology Times talks with Andrew Lee, MD, about his presentation "Neuro op mimics of thyroid eye disease" at this year's Hawaiian Eye and Retina 2024 Meeting.

According to a study by Johns Hopkins Children’s Center researchers, AI-driven cameras that take images of the back of the eye and require no eye drops can be used to close care gaps.

According to an American Academy of Ophthalmology news release, Edmond’s priorities during her term include addressing physician and staff shortages and protecting patient safety at a time when nonphysicians are trying to expand their scope of practice into eye surgery.

Company presenting data from the Phase II AAVIATE trial of suprachoroidal ABBV-RGX-314 for the treatment of wet age-related macular degeneration January 16 at the Hawaiian Eye and Retina 2024 Meeting.

The company is showcasing its lasers at the Hawaiian Eye and Retina 2024 meeting, being held January 13-19 at the Grand Wailea Resort in Maui.

Studies aim to develop a clinically useful biomarker of retinal capillary changes to monitor the development of a prevalent form of systemic vascular disease and cerebrovascular disease.

Because acetylcholinesterase inhibitors have anti-inflammatory effects, authors of the study wanted to determine if these drugs reduce the risk of AMD in patients with Alzheimer’s disease.

The GLYCO Phase 2 US clinical trial will evaluate AVD-104 for the management of diabetic macular edema (DME).

The trial will use vision preservation as a primary outcome measure, according to Annexon